Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
What the Research Actually Shows Published research on AOD-9604 describes: Modest body fat reduction in preclinical and early clinical settings Reduced triglycerides in some studies Minimal effect on IGF-1 confirmed across the clinical dataset Good tolerability adverse event rates in the phase 2 obesity trials were comparable to placebo Variable weight loss some patients respond better than others, consistent with many metabolic interventions The effect size in phase 2 obesity trials was modest typically in the range of a few pounds over the study period
X.YangX
This is particularly beneficial for patients with digestive conditions or those who experience gastrointestinal intolerance to oral supplements
Weinheim: Wiley-VCH
Our holistic approach means we can coordinate our approaches to maximize your benefits
